Landos Biopharma, Inc. financial data

Location
Blacksburg, VA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2024 - 09 May 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 730% % -20%
Debt-to-equity 16% % 30%
Return On Equity -73% % -8.9%
Return On Assets -63% % -5.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,119,226 shares -90%
Common Stock, Shares, Outstanding 3,116,729 shares -90%
Common Stock, Value, Issued $31,000 USD -90%
Weighted Average Number of Shares Outstanding, Basic 6,207,637 shares -4.3%
Weighted Average Number of Shares Outstanding, Diluted 6,207,637 shares -4.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $11,824,000 USD -35%
General and Administrative Expense $13,719,000 USD -1.2%
Operating Income (Loss) $25,543,000 USD 20%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $24,798,000 USD 19%
Net Income (Loss) Attributable to Parent $24,798,000 USD 19%
Earnings Per Share, Basic -4 USD/shares 61%
Earnings Per Share, Diluted -4 USD/shares 61%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $29,004,000 USD -36%
Assets, Current $29,896,000 USD -42%
Assets $29,896,000 USD -42%
Accounts Payable, Current $1,565,000 USD -32%
Accrued Liabilities, Current $5,177,000 USD 178%
Liabilities, Current $6,742,000 USD 62%
Liabilities $6,742,000 USD 62%
Retained Earnings (Accumulated Deficit) $164,259,000 USD -18%
Stockholders' Equity Attributable to Parent $23,154,000 USD -51%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $23,154,000 USD -51%
Liabilities and Equity $29,896,000 USD -42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,498,000 USD -4%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 20,000,000 shares -90%
Common Stock, Shares, Issued 3,116,729 shares -90%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $29,054,000 USD -36%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $24,877,000 USD 17%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $187,382,000 USD 0.69%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $1,007,000 USD -20%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%